Interleukin Related
Interleukin is a group of cytokines that mediates cell-cell communication. It plays a critical role in inflammation/immunity and regulates cell proliferation, differentiation and migration etc.
Products for Interleukin Related
- Cat.No. Product Name Information
- GC37999 β-Anhydroicaritin β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties.
- GC65373 (R)-IL-17 modulator 4 (R)-IL-17 modulator 4 is the R-configure of IL-17 modulator 4.
- GC35184 7,3',4'-Tri-O-methylluteolin 7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone), a flavonoid compound, possesses potent anti-inflammatory effects in LPS-induced macrophage cell line mediated by inhibition of release of inflammatory mediators, NO, PGE2, and pro-inflammatory cytokines.
- GC35214 A-9758 A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release.
- GC35373 Apilimod Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
- GC35374 Apilimod mesylate Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
- GC31661 APY0201 APY0201 is a potent PIKfyve inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P2 in the presence of in the presence of [33P]ATP with an IC50 of 5.2 nM.
- GC61796 Armillarisin A Armillarisin A has the potential for the ulcerative colitis (UC) study.
-
GC68702
Astegolimab
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that can block IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab has potential for use in research on chronic obstructive pulmonary disease (COPD).
- GC35440 AX-024 AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM.
- GC19046 AX-024 hydrochloride AX-024 hydrochloride is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.
- GC18126 Balsalazide anti-inflammatory drug
- GC35466 Balsalazide sodium hydrate Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
- GC66331 Basiliximab Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation.
- GC39346 Benralizumab Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity.
-
GC68807
Briakinumab
Briakinumab (ABT-874) is a fully human monoclonal antibody that targets and neutralizes IL-12/23p40. Briakinumab specifically targets and neutralizes both IL-12 and IL-23. It is being studied for its potential use in rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
- GC67748 Brodalumab
- GC66328 Canakinumab Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.
- GC67859 Clerodendrin
- GN10118 Desacetyl asperulosidic acid
- GC65161 Di-O-methyldemethoxycurcumin Di-O-methyldemethoxycurcumin, a curcuminoid analog, inhibits IL-6 production with an EC50 of 16.20 μg/mL.
- GC15320 Diacerein IL receptor inhibitor
- GC10801 Disulfiram An irreversible inhibitor of aldehyde dehydrogenase
- GC66407 Etokimab Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis.
- GC30910 Eucalyptol (1,8-Cineole) A bicyclic monoterpene with diverse biological activities
-
GC69104
Fezakinumab
Fezakinumab is a monoclonal antibody against interleukin 22 (IL-22). It can be used in the research of inflammatory diseases such as psoriasis and rheumatoid arthritis.
- GC36106 Gamma-glutamylcysteine (TFA) Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA, an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).
- GC30831 GIBH-130 GIBH-130 is an effective inhibitor of neuroinflammation.
- GN10450 Ginsenoside F3
- GN10254 Ginsenoside Rc
- GN10538 Ginsenoside Rh1
- GC62685 Guselkumab Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit.
- GC13074 HU 211 NMDA antagonist, novel and non-competitive
- GC60914 Hydrocortisone hemisuccinate Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-in?ammatory drug (SAID).
- GC65291 IL-15-IN-1 IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM.
- GC63018 IL-17 modulator 1 disodium IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685.
- GC63019 IL-17 modulator 4 IL-17 modulator 4 is a prodrug of IL-17 modulator 1.
- GC34372 IL-17A antagonist 1 IL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a Kd of 0.66 μM and an IC50 of 1.14 μM.
- GC34371 IL-17A antagonist 3 IL-17A antagonist 3 is an IL-17A antagonist, compound 3.
- GC62659 IL-17A inhibitor 1 IL-17A inhibitor 1 (example 24) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells.
- GC64236 IL-17A modulator-1 IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9.
- GC64269 IL-17A modulator-2 IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27.
- GC31948 IX 207-887 IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1).
- GC62224 Ixekizumab Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM).
-
GC12331
JC-1
JC-1(CBIC2) is a cationic carbonyl cyanine fluorescent dye.
- GC62527 Kansuinine A Kansuinine A inhibits IL-6-induced Stat3 activation.
-
GC69365
Lebrikizumab
Lebrikizumab is a humanized monoclonal antibody of the IgG4 class that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used in research for asthma.
-
GC19070
LMT-28
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130
- GC66347 Mepolizumab Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
- GC16007 Methylthiouracil antithyroid preparation
- GN10055 Mulberroside A
-
GC69534
Nadunolimab
Nadunolimab is a human IgG1 monoclonal antibody that targets IL1RAP. Nadunolimab blocks the signaling of IL-1α and IL-1β and triggers antibody-dependent cell cytotoxicity. Nadunolimab can be used for cancer research.
- GC39070 Negletein Negletein is a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells.
- GC68341 Nemolizumab
- GN10429 Neochlorogenic acid
- GC50243 NFAT inhibitor, Cell Permeable NFAT inhibitor, Cell Permeable is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor.
- GC31934 NFAT Transcription Factor Regulator NFAT Transcription Factor Regulator is an IL-2 synthesis inhibitor with an IC50 of 182 nM.
-
GC69561
Nidanilimab
Nidanilimab (CAN04) is a fully humanized monoclonal antibody against IL1RAP, with a Kd value of 1.10 pM. Nidanilimab blocks the signaling pathways of IL1α and IL1β, and stimulates the immune system to destroy tumor cells. Nidanilimab can be used for research on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
- GC36757 NO-prednisolone NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone.
- GC33873 Nosantine racemate (NPT-15392 racemate) Nosantine racemate (NPT-15392 racemate) is the racemate of Nosantine.
- GC19741 NSC 247030 NSC 247030 is an inhibitor of interleukin-2 (IL-2) production.
-
GC69595
NSC61610
NSC61610 disrupts the binding between hIL-18 and ectromelia virus IL-18BP. NSC61610 inhibits the formation of hIL-18:ectvIL-18BP complex with an IC50 of approximately 6 uM.
-
GC69621
Olokizumab
Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab can be used in the research of rheumatoid arthritis (RA).
-
GC69631
Ordesekimab
Ordesekimab (AMG 714; PRV-015) is a human IgG1κ monoclonal antibody that targets IL-15 (Interleukin Related). Ordesekimab inhibits the interaction between IL-15 and the common γ chain of IL-2Rβ and IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has potential for researching non-responsive celiac disease (NRCD).
-
GC69641
Oxelumab
Oxelumab (R 4930) is a human monoclonal antibody that targets the OX40 ligand (OX40L). Oxelumab can be used for research on asthma.
-
GC69713
Pivekimab
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. It can be used for research on blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
GC31312
RCGD423
A gp130 modulator
- GC39430 Reslizumab Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
-
GC69818
Risankizumab
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that targets the IL-23 p19 subunit (Kd <10 pM) and can inhibit human IL-23-induced IL-17 production in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to study immune and inflammatory diseases such as psoriasis, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
- GC60327 RO2959 hydrochloride RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM.
- GC61248 RO2959 monohydrochloride RO2959 monohydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM.
-
GC69828
Rolinsatamab
Rolinsatamab is an effective dual inhibitor of IL-4 and IL-13, which is a fully humanized bispecific monoclonal antibody. Rolinsatamab binds to the chimeric antigen receptor sequence T cells. It can be used for research on immune diseases.
- GC31804 RP-54745 RP-54745 is an inhibitor of macrophage stimulation and interleukin-1 production, and a potential antirheumatic compound.
- GC66414 Sarilumab Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis.
- GC66342 Satralizumab Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
- GC15714 SC 144 Gp130 inhibitor
- GC37603 SC144 hydrochloride SC144 hydrochloride is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 hydrochloride binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 hydrochloride shows potent inhibition of gp130 ligand-triggered signaling. SC144 hydrochloride induces apoptosis in human ovarian cancer cells.
- GC62444 SDZ 224-015 SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1.
- GC39815 Semapimod tetrahydrochloride Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.
- GC68336 Siltuximab
- GC62370 Sodium thiocyanate Sodium thiocyanate reduces plasma levels of the pro-inflammatory cytokine IL-6, and increases the anti-inflammatory cytokine IL-10 levels.
- GC64482 SP4206 SP4206 is an IL-2/IL-2Rα interaction inhibitor.
-
GC69937
Spesolimab
Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 plays an important role in the immune system, and Spesolimab can be used for research on palmoplantar pustulosis (PPP). The reduction of biomarkers associated with innate, Th1/Th17, and neutrophil pathways is related to Spesolimab.
-
GC69943
SRI-42127
SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulatory factor that binds to ARE elements, and HuR translocation can promote the production of inflammatory cytokines in glial cells. SRI-42127 can disrupt mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial activation, reducing the recruitment/chemotaxis of neutrophils and monocytes.
- GC17961 Suplatast Tosylate Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis.
-
GC37705
Suramin
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor.
- GC16832 Suramin hexasodium salt Suramin hexasodium salt(Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor.
- GC50350 TC JL 37 Potent TYK2 inhibitor
-
GC70004
Tebentafusp
Tebentafusp (IMCgp100) is a bispecific fusion protein that targets gp100, a melanoma-associated antigen. Tebentafusp guides T cells to kill tumor cells expressing gp100 through its high-affinity T cell receptor (TCR) binding domain and anti-CD3 T cell binding domain. Tebentafusp induces the production of inflammatory cytokines and cytolytic proteins, leading to direct lysis of tumor cells.
-
GC37809
Tocilizumab
Tocilizumab, as a humanised monoclonal antibody, can target both membrane-bound and soluble forms of the IL-6 receptor.
-
GC70045
Tozorakimab
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody that targets interleukin-33. It can be used for research on chronic obstructive pulmonary disease.
- GC66350 Tralokinumab Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD).
- GC31659 Tyk2-IN-4 (BMS-986165) Tyk2-IN-4 (BMS-986165) (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain.
- GC37850 Tyrphostin A1 Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
- GC50511 UCLA GP130 2 UCLA GP130 2 is a potent, brain-penetrant and orally active GP130 receptor agonist.
- GC34213 Ustekinumab (Anti-Human IL-12/IL-23, Human Antibody) Ustekinumab (Anti-Human IL-12/IL-23, Human Antibody) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
- GC31791 Veledimex (INXN-1001) Veledimex (INXN-1001) (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system.
- GC33870 Veledimex racemate (RG-115932 racemate) Veledimex racemate (RG-115932 racemate) (INXN-1001 racemate) is the racemate of veledimex.
- GC30705 Veledimex S enantiomer (INXN-1001 S enantiome) Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.
- GC10210 VGX-1027 Immunomodulator